BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More
The Pharma Data
DECEMBER 2, 2020
aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. Financial details of the agreement were not disclosed.
Let's personalize your content